Analyze at the Speed of Thought - Why it’s More than a Tagline

Analyze at the Speed of Thought - Why it’s More than a Tagline

The concept of company mission statements and their relevance are as polarizing a debate as any in the annals of management science. Some argue that a company's mission gives its purpose and establishes a framework for formulating a corporate strategy.

Back to Excel - A Framework for Building Responsive BI

Back to Excel - A Framework for Building Responsive BI

For decades, business users were able to analyze small sets of data independently using off-the-shelf tools like Microsoft Excel. Business users and technical non-IT personnel were able to perform a variety of tasks to extract value

Search-Based Analytics, the next Frontier in Business Intelligence

Search-Based Analytics, the next Frontier in Business Intelligence

Business Intelligence (BI) represents the collection of tools and technologies used to transform raw data into useful insights. BI and related analytics is one of the fastest growing industries with Gartner estimating the market to grow to $22.8bn by 20201.

Coming, the Market Access Era of DTC Campaigns

Coming, the Market Access Era of DTC Campaigns

Market access teams perform the critical task of articulating a drug’s value proposition to key payer decision-makers.  Historically, that has meant MSLs, payer marketers, HEOR professionals...

Other People's Lives: Rubbernecking the Anthem-ESI contract dispute

Other People's Lives: Rubbernecking the Anthem-ESI contract dispute

The Internets were ablaze earlier this week as Reuters broke the news that Anthem is looking for a way to end their long-term pharmacy benefit agreement with Express Scripts (ESI). Given the strategic importance of the Anthem business to Express Scripts (14% of ESI revenue), this was for once, a development with implications to match the headlines.

Medicare Part D and Specialty Drugs - A Tale of Two Segments

Medicare Part D and Specialty Drugs - A Tale of Two Segments

This is a follow-up to our last post about the affordability of specialty drugs within the Medicare Part D population. First, a quick review:

  • Nearly half of Medicare recipients have annual incomes less than $24,150 and a full quarter of the recipients have annual incomes lower than $14,350

Medicare Part D & Specialty Drugs - A Crisis in the Making

Medicare Part D & Specialty Drugs - A Crisis in the Making

Since its inception, Medicare Part D has been a boon to seniors with a 2015 Medicare Today national survey showing that 89% of seniors are satisfied with their Part D drug coverage. In the same survey, 71% of seniors say they derive a great deal of peace of mind from their prescription drug coverage.

Quick Thoughts on the Express Scripts SafeGuardRx℠ Program

Quick Thoughts on the Express Scripts SafeGuardRx℠ Program

Express Scripts just fired the next shot across the bow in its much-publicized quest to control prescription drug costs. Beginning 2016, ESI is launching the SafeGuardRx℠ program, marketed as a “collection of novel solutions that will transform the pharmacy benefi

Why the FTC Should be Wary of Approving the Anthem-Cigna Merger

Why the FTC Should be Wary of Approving the Anthem-Cigna Merger

Anthem’s recently proposed purchase of Cigna is expected to create the largest health insurance company in the US. If the transaction goes through, it will cap a dramatic episode in the continuing consolidation of the payer market.

Impending Payer Acquisitions: 4 Things to Watch For

Impending Payer Acquisitions: 4 Things to Watch For

Even the most ardent advocate for a single-payer system in the US would not have seen this convoluted path to get there: the rapid consolidation of the health insurance industry. Just in the last few weeks, there has been news about three major potential acquisitions: Aetna-Humana, Wellpoint-Cigna, and Centene-HealthNet.

A Data Science Perspective on King vs. Burwell

A Data Science Perspective on King vs. Burwell

Any moment now, the supreme court will rule on a case that challenges the legality of subsidies granted to eligible low and middle-income populations buying insurance through the federal health exchange. The Kaiser Family Foundation’s analysis of the case’s impact paints a stark picture of what’s at stake.

Why You Need a Revenue Protection Plan for Your Managed Markets Team

Why You Need a Revenue Protection Plan for Your Managed Markets Team

Research has shown that a 1% loss in net price can lead to a >5% decrease in operating profits. With the ever-increasing payer pressure for higher rebates, price protection, and other forms of concessions managed markets teams need to adopt best practices to minimize revenue leakage from unintended contracting events.

Setting Post-Deal Contract Goals? Time to Pay Attention to Payer Channel Dynamics

Setting Post-Deal Contract Goals? Time to Pay Attention to Payer Channel Dynamics

At Stotle, we often work with brands that have a large number of managed care contracts. These brands invest substantial Gross-To-Net dollars to secure the appropriate formulary access.

When contracts are signed, there is an expectation that the account teams will generate sufficient pull-through to justify the investment.